Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1508 ARTÍCULOS , VIENDO DEL 706 AL 720

The anti-dementia drug candidate, (-)-clausenamide, improves memory impairment through its multi-target effect

Chu S, Liu S, Duan W, Cheng Y, Jiang X, Zhu C, Tang K, Wang R, Xu L, Wang X, Yu X, Wu K, Wang Y, Wang M, Huang H, Zhang J.

Pharmacol Ther. 2016 Jun;162:179-87. doi: 10.1016/j.pharmthera.2016.01.002. Epub 2016 Jan 23.

Homocysteine and Mild Cognitive Impairment: Are These the Tools for Early Intervention in the Dementia Spectrum?

Ansari Z.

J Nutr Health Aging. 2016 Feb;20(2):155-60. doi: 10.1007/s12603-015-0576-y.

Emerging amyloid disease-modifying drugs for Alzheimer's disease

Galimberti D, Scarpini E.

Expert Opin Emerg Drugs. 2016;21(1):5-7. doi: 10.1517/14728214.2016.1146678. Epub 2016 Feb 15.

Nicotinic Acetylcholine Receptors in the Pathophysiology of Al zheimer's Disease: The Role of Protein-Protein Interactions in Current and Future Treatment

Thomsen MS, Andreasen JT, Arvaniti M, Kohlmeier KA.

Curr Pharm Des. 2016;22(14):2015-34. doi: 10.2174/1381612822666160127112357.

A synopsis on the linkage between age-related dementias and vascular disorders

Chibber S, Alexiou A, Alama MN, Barreto GE, Aliev G, Ashraf GM.

CNS Neurol Disord Drug Targets. 2016;15(2):250-8. doi: 10.2174/1871527315666160202121809.

Impact of caregiver readiness on outcomes of a nonpharmacological intervention to address behavioral symptoms in persons with dementia

Gitlin LN, Rose K.

Int J Geriatr Psychiatry. 2016 Sep;31(9):1056-63. doi: 10.1002/gps.4422. Epub 2016 Feb 2.

Tau, amyloid, and hypometabolism in the logopenic variant of primary progressive aphasia

Pascual B, Masdeu JC.

Neurology. 2016 Feb 2;86(5):487-8. doi: 10.1212/WNL.0000000000002340.

Cholesterol, 24-Hydroxycholesterol, and 27-Hydroxycholesterol as Surrogate Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer's Disease: A Meta-Analysis

Wang HL, Wang YY, Liu XG, Kuo SH, Liu N, Song QY, Wang MW.

J Alzheimers Dis. 2016;51(1):45-55. doi: 10.3233/JAD-150734.

Differential Impairment of Cognitive and Affective Mentalizing Abilities in Neurodegenerative Dementias: Evidence from Behavioral Variant of Frontotemporal Dementia, Alzheimer's Disease, and Mild Cognitive Impairment

Dodich A, Cerami C, Crespi C, Canessa N, Lettieri G, Iannaccone S, Marcone A, Cappa SF, Cacioppo JT.

J Alzheimers Dis. 2016;50(4):1011-22. doi: 10.3233/JAD-150605.

Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials

Kennedy RE, Cutter GR, Wang G, Schneider LS.

J Alzheimers Dis. 2016;50(4):1205-15. doi: 10.3233/JAD-150847.

Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study

Nagata T, Shinagawa S, Nakajima S, Plitman E, Mihashi Y, Hayashi S, Mimura M, Nakayama K.

J Alzheimers Dis. 2016;50(3):839-45. doi: 10.3233/JAD-150869.

Progressive Language Impairment in an English-Italian Bilingual Woman With Alzheimer Disease: An 18-Month Follow-up

D'Antonio F, Imbriano L, Campanelli A, de Lena C, Trebbastoni A.

Alzheimer Dis Assoc Disord. 2016 Oct-Dec;30(4):354-356. doi: 10.1097/WAD.0000000000000139.

Dementia and Cognitive Impairment Prevalence and Associated Factors in Indigenous Populations: A Systematic Review

de Souza-Talarico JN, de Carvalho AP, Brucki SM, Nitrini R, Ferretti-Rebustini RE.

Alzheimer Dis Assoc Disord. 2016 Jul-Sep;30(3):281-7. doi: 10.1097/WAD.0000000000000140.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias